Remdesivir for COVID-19 | Bacterial vaginosis | Pain suppression

Early results show benefit of remdesivir for COVID-19; beneficial bacteria prevent recurring bacterial vaginosis; pain-suppression in brain

June 2, 2020 Edition

COVID-19 is an emerging, rapidly evolving situation, and we at NIH are doing everything we can toward the development of diagnostics, therapeutics, and vaccines. You can find the latest public health information from CDC at www.coronavirus.gov and the latest research information from NIH at www.nih.gov/coronavirus. Meanwhile, science continues to progress on many other fronts, and we will continue to try to bring you stories across a wide range of topics.

SARS-COV-2 virus particles

Early results show benefit of remdesivir for COVID-19

Early clinical trial results support the use of remdesivir for patients with severe COVID-19 who require supplemental oxygen, but more research is needed to improve outcomes for people with COVID-19.


Female doctor talking to woman

Beneficial bacteria prevent recurring bacterial vaginosis

An experimental treatment for a common infection called bacterial vaginosis significantly reduced the rates of recurrence.


Pain suppression neurons in mouse brain

Scientists find new pain-suppression center in the brain

Scientists identified a group of neurons in mice that blunt pain within the brain. Such neurons could be promising targets for new non-addictive therapies for chronic pain.


Popular Stories

Connect with Us

FB

Facebook

RM Feed

RSS Feed


This email was sent to ymilov@gmail.com using GovDelivery Communications Cloud on behalf of: National Institutes of Health (NIH) · 9000 Rockville Pike · Bethesda MD 20892 · 301-496-4000 / TTY 301-402-9612 GovDelivery logo